Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States

ABSTRACT

Due to COVID-19, vaccinations dropped in 2020 and 2021. We estimated the impact of reduced recombinant zoster vaccine (RZV) use on herpes zoster (HZ) cases, complications, and quality-adjusted life-year (QALY) losses among older adults. Various scenarios were compared with Markov models using data from national sources, clinical trials, and literature. Missed series initiations were calculated based on RZV distributed doses. In 2020, 3.9 million RZV series initiations were missed, resulting in 31,945 HZ cases, 2,714 postherpetic neuralgia cases, and 610 lost QALYs. Scenarios further projected disease burden increases if individuals remain unvaccinated in 2021 or the same number of initiations are missed in 2021. Health professionals should emphasize the importance of vaccination against all preventable diseases during the COVID-19 era.

KEYWORDS:

• COVID-19
• herpes zoster
• shingles
• postherpetic neuralgia
• recombinant zoster vaccine
• vaccine
• immunization
• public health

Introduction

Herpes zoster (HZ [i.e., shingles]), caused by reactivation of the varicella-zoster virus (VZV, chickenpox), is a common ailment in adult populations. Nearly one in three individuals in the United States (US) develop HZ at some point in their lifetime, with an estimated 1 million individuals diagnosed with HZ annually.¹

HZ is characterized by a painful rash that typically appears on one side of the back, chest, or abdomen, associated with one or more affected dermatomes. Some patients describe the pain as an intense burning sensation, which can last for months or even years after the rash goes away. This long-lasting pain is called postherpetic neuralgia (PHN), and it is the most common complication of HZ.² Other complications include ocular, neurological, cutaneous, and non-pain complications.² HZ impacts sleep, work, and an individual’s ability to perform other daily activities.^3,4

Recombinant zoster vaccine (RZV, Shingrix, GSK) is licensed in the US and recommended by the Advisory Committee on Immunization Practices to prevent HZ in adults ≥ 50 years, as well as adults ≥ 19 years who are or will be immunodeficient or immunosuppressed due to disease or therapy.^5,6 In adults aged ≥ 50 years, vaccine efficacy in preventing HZ has been shown to be greater than 90%.^7–9 Vaccine efficacy in reducing HZ burden of illness due to pain and HZ burden of interference on activities of daily living was also greater than 90% in individuals aged ≥ 50 years.¹⁰

With the COVID-19 pandemic, non-COVID-19 vaccination rates have declined for various reasons, including lockdown restrictions. However, given that HZ is caused by the reactivation of latent VZV [i.e., chickenpox], even individuals who are isolated are still at risk of HZ. To address the issue of decreased vaccination coverage, the Centers for Disease Control and Prevention’s (CDC) guidance on HZ vaccination specifies that HZ vaccination should not be delayed or discontinued because of the pandemic unless a patient is suspected or confirmed to have COVID-19 because this preventive care is essential for older adults.¹¹ The guidance also notes that health care providers and eligible patients should strive to administer the two RZV doses within the recommended interval of 2 to 6 months.¹¹

In this study, we explored the impact of decreased HZ vaccination by estimating the number of HZ cases, complications, and quality-adjusted life-year (QALY) losses that would have been avoided if vaccination coverage had continued at the same rate as observed prior to the pandemic period.

Methods

Model overview

A multi-cohort Markov model estimated the impact of missed RZV vaccinations on avoidable HZ cases, PHN cases, and complication cases among US adults aged ≥ 50 years (Figure 1). The model includes a 1-year cycle length, with five age-specific cohorts (50–59, 60–64, 65–69, 70–79, and ≥ 80 years) that are followed for a period of 1–2 years after their missed vaccinations, depending on the scenario. The age distribution of the population in the model is reflective of the population of adults ≥ 50 years of age in the US. A multicohort model, instead of a single cohort model, was employed to better account for the increasing risk of HZ as individuals age as well as varying risk of HZ-related complications and QALY losses by age. Specific details on the model’s underlying structure, inputs, data sources, and assumptions have been previously described.¹² The base-case analysis compares scenarios with and without missed RZV vaccinations between April through December 2020, with a 1-year follow-up period.

Figure 1. Markov model structure. HZ = herpes zoster; PHN = postherpetic neuralgia Figure copied with permission from Vaccine.¹²

Model inputs

Model inputs related to the age distribution of the US population, mortality rates, HZ epidemiology, baseline utilities, and QALY losses per case of HZ and per dose of RZV (for adverse event-related QALY losses) were obtained from standard US sources and published literature.¹² RZV year 1 efficacy values against HZ and PHN were obtained from clinical trial data,^7,8 consistent with the previously published model.¹² Two-dose RZV waning estimates were updated with more recent data on long-term persistence, which resulted in annual waning rates of 1.5% and 2.3% among individuals < 70 years and ≥ 70 years, respectively.^13,14 In the scenario without missed vaccinations, 1-dose RZV coverage was assumed to be 100%, and 2^nd dose compliance was set at 80% based on recent data on RZV series completion.¹⁵ An assumption of 100% first dose coverage was used, as the analyses focused on the incremental outcomes resulting from vaccination of the population estimated to have missed series initiations in 2020 (or 2021 in scenario analyses), rather than outcomes for the entire US population. The model assumed that the RZV doses were administered two months apart as per label¹⁶ and that the series completion rate did not change during the pandemic.

Missed doses were estimated using data on RZV distributed doses and an assumed 43% reduction in RZV vaccinations during the pandemic, based on data reported by the CDC on reductions in RZV use among Medicare beneficiaries during specific weeks in 2020 as compared with the corresponding weeks in 2019.¹⁷ Hong et al.¹⁷ reported that RZV use decreased by 62% during the week following the national emergency declaration (week of March 13, 2020) and continued decreasing to a low of an 89% decrease (week of April 12, 2020) before rebounding to a decrease of 43% by the end of the study period (week of July 12, 2020). Missed RZV series initiations were then calculated from the missed doses assuming an 80% two-dose completion rate.¹⁵

Analyses

The base-case analysis assumed a 43% reduction in RZV use between April through December of 2020 and followed individuals with a missed series initiation for a period of 1 year. Because data on reduced RZV use were not available through the end of 2020, a one-way sensitivity analysis was also conducted, assuming a more conservative 30% reduction in RZV use between April and December 2020. Two scenario analyses were also conducted:

• Scenario analysis 1: assuming that individuals with missed RZV series initiations in 2020 remain unvaccinated in 2021

• Scenario analysis 2: assuming that individuals with missed RZV series initiations in 2020 remain unvaccinated in 2021 (as above) and that the same number of individuals missed RZV series initiations in 2021

For both scenario analyses, the follow-up period was 2 years, with QALYs discounted at 3% per year.

Results

Assuming a 43% reduction in RZV use due to the COVID-19 pandemic, an estimated 21 million RZV doses were expected to be distributed in 2020, including approximately 16.5 million doses between April through December 2020. Of the 9.2 million RZV series initiations expected between April and December 2020, an estimated 5.4 million series were initiated, and 3.9 million series initiations were missed (Figure 2). In the base-case analysis, these missed RZV series initiations resulted in projections of 31,945 avoidable HZ cases, 2,714 avoidable PHN cases, 3,607 avoidable complication cases, and 610 avoidable QALY losses over the 1-year follow-up period (Table 1). Among the avoidable complication cases, ocular complications were most frequently projected (33.8%), followed by neurological complications (32.8%), other non-pain complications (18.5%), and cutaneous complications (14.9%) (Figure 3).

Table 1. Base-case and scenario analysis results: avoidable cases and QALY losses due to missed RZV vaccinations

Outcomes	Base-case	Scenario analysis 1^a	Scenario analysis 2^b
Avoidable cases
HZ	31,945	63,117	95,062
PHN	2,714	5,356	8,070
Complications	3,607	7,122	10,730
Avoidable QALY losses	610	1,185	1,795

HZ = herpes zoster; PHN = postherpetic neuralgia; QALY = quality-adjusted life-year; RZV = recombinant zoster vaccine.

^aScenario analysis 1 assumes individuals with missed RZV series initiations in 2020 remain unvaccinated in 2021.

^bScenario analysis 2 assumes that individuals with missed RZV series initiations in 2020 remain unvaccinated in 2021 (as above) and that the same number of individuals missed RZV series initiations in 2021.

Figure 2. Estimated missed RZV series initiations in base-case, sensitivity, and scenario analyses. RZV = recombinant zoster vaccine.

Figure 3. Base-case and scenario analysis results: avoidable complication cases due to missed RZV vaccinations. RZV = recombinant zoster vaccine Note: Scenario analysis 1 assumes individuals with missed RZV series initiations in 2020 remain unvaccinated in 2021. Scenario analysis 2 assumes that individuals with missed RZV series initiations in 2020 remain unvaccinated in 2021 (as above) and that the same number of individuals missed RZV series initiations in 2021.

In a one-way sensitivity analysis assuming 30% RZV reduction during the pandemic, an estimated 13.5 million RZV doses were expected to be distributed between April and December 2020. During this period, 7.5 million RZV series initiations were expected, with approximately 2.2 million initiations missed (Figure 2). As a result of these missed RZV series initiations, the model projected 18,020 avoidable HZ cases, 1,531 avoidable PHN cases, 2,035 avoidable complication cases, and 344 avoidable QALY losses over the 1-year follow-up period.

Results from Scenario Analysis 1 indicate that if the estimated 3.9 million individuals who missed RZV series initiations in 2020 remain unvaccinated in 2021, avoidable HZ cases, PHN cases, complication cases, and QALY losses will all increase over a follow-up period of 2 years (Table 1 and Figure 3). Additionally, if these 3.9 million individuals remain unvaccinated in 2021 and the same number of 3.9 million additional RZV series initiations are missed in 2021 (Scenario Analysis 2), projected outcomes over this 2-year follow-up period increase further to a high of 95,062 avoidable HZ cases, 8,070 avoidable PHN cases, 10,730 avoidable complication cases, and 1,795 avoidable QALY losses (Table 1 and Figure 3).

Discussion

The current study estimated that 31,945 avoidable HZ cases were expected as a result of the decrease in HZ vaccination rates due to the pandemic in the US. These HZ cases included over 2,700 avoidable PHN cases, over 3,600 avoidable complication cases, and over 600 avoidable QALY losses that were projected by the model, highlighting the added HZ-related burden attributed to the COVID-19 pandemic beyond the substantial morbidity and mortality posed by primary COVID-19 cases. Over the short term, increases in HZ-related burden were consistently observed across the various sensitivity and scenario analyses conducted (e.g., with avoidable HZ cases over a 1- to 2-year follow-up period ranging from 18,020 to 95,062 across analyses).

Previous analyses have reported reductions in child, adolescent, and adult vaccination coverage in the US due to the COVID-19 pandemic.^17–19 However, to our knowledge, this is the first analysis that has modeled the impact of missed vaccinations for other vaccine-preventable diseases on disease-related health outcomes. This type of analysis is particularly relevant for HZ, where individuals remain at risk of developing HZ regardless of COVID-related mitigation efforts (e.g., lockdown restrictions, social distancing, use of face masks).

The current analysis focused on short term HZ-related health outcomes resulting from missed RZV vaccinations during the pandemic and did not model the impact of these avoidable HZ cases on associated health care resource use (HCRU) and costs. Additional data on healthcare seeking behaviors during the pandemic would be needed to estimate the impact of reduced RZV use on HZ-related HCRU and costs. In addition to the burden experienced by unvaccinated individuals who experienced HZ, these avoidable cases may have also been competing for scarce health care resources during the pandemic, which is not captured in the current analysis. Additional data are also needed to improve understanding of the impact of the pandemic on HZ-related outcomes over the longer term, depending on whether HZ vaccination coverage continues to lag into 2021 and beyond.

In this study, no increased risk of HZ during the COVID-19 pandemic has been assumed. However, previous studies have proposed a potential association between HZ and the COVID-19 pandemic.^20–22 Several hypotheses could be postulated on why there may be an increased risk of HZ during lockdowns and restrictions. Increased levels of stress and depression have been shown to be associated with an increased risk of HZ,^23,24 while mental health domains such as anxiety and depression are risk factors for developing PHN.^25,26 In addition, COVID-19 induced T-cell dysfunction, and aberrant IL-17 signaling have been suggested to also increase the risk of developing HZ.^27,28

Findings from the current study indicate that, in the US, reduced RZV use during the pandemic likely resulted in avoidable cases of HZ. Since HZ is a global disease and the COVID-19 pandemic has spread worldwide, the global impact of reduced RZV use during the pandemic is likely significant. In addition to vaccination against COVID-19, the results underscore the need for older adults to continue to be vaccinated against other preventable diseases, including HZ. It is important that vaccine recipients and health care providers are informed of the disease risk and impact of avoiding vaccinations to ensure that vaccine coverage levels are restored to pre-pandemic levels and maintained or improved over the long term.

Abbreviations

Table

COVID-19	Corona Virus Disease 2019 caused by SARS-CoV-2
CDC	Centers for Disease Control and Prevention
RZV	recombinant zoster vaccine
QALY	quality-adjusted life-year
HZ	herpes zoster
PHN	postherpetic neuralgia
US	United States
VZV	varicella-zoster virus
ZBPI	Zoster Brief Pain Inventory
HCRU	health care resource use

Contributorship

All authors participated in the design or implementation or analysis, and interpretation of the study; and the development of this manuscript. All authors had full access to the data and gave final approval before submission. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The work described was carried out in accordance with the recommendations of the International Committee of Medical Journal Editors for conduct, reporting, editing, and publication of scholarly work in medical journal.

Trademark

Shingrix is a trademark owned by or licensed to the GSK group of companies.

Acknowledgments

The authors would like to thank Business & Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Diego Collin coordinated manuscript development and editorial support. Esther van de Vosse provided medical writing support.

Disclosure statement

All authors are employed by the GSK group of companies. DC, EML, NL, and SP hold shares in the GSK group of companies. The authors declare no other financial and non-financial relationships and activities.

Additional information

Funding

GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000222) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took in charge all costs related to the development and publication of this manuscript.